Drug-repositioning opportunities for cancer therapy: Novel molecular targets for known compounds

Drug Discovery Today

Volumn 21, Issue 1, 2016, Pages 190-199

  Würth, Roberto ^a   Thellung, Stefano ^a   Bajetto, Adriana ^a   Mazzanti, Michele ^b   Florio, Tullio ^a   Barbieri, Federica ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; DIGITOXIN; DIGOXIN; DISULFIRAM; ITRACONAZOLE; METFORMIN; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CELL HETEROGENEITY; DRUG REPOSITIONING; EFFECTIVE CONCENTRATION; HUMAN; NONHUMAN; ONCOLOGY; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG REPOSITIONING; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84960199759     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.09.017     Document Type: Review

References (127)

1. J. Langedijk, and et al. Drug repositioning and repurposing: terminology and definitions in literature Drug Discov. Today 20 2015 1027 1034
2. N. Galie, and et al. Sildenafil citrate therapy for pulmonary arterial hypertension N. Engl. J. Med. 353 2005 2148 2157
3. Z.Y. Pessetto, and et al. Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor Mol. Cancer Ther. 13 2014 2276 2287
4. J.J. Gills, and et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo Clin. Cancer Res. 13 2007 5183 5194
5. T. De Schutter, and et al. Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir Mol. Cancer 12 2013 158
6. S. Liekens, and et al. The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors Oncotarget 6 2015 4633 4648
7. K. Shameer, and et al. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification Curr. Top. Med. Chem. 15 2015 5 20
8. H. Xu, and et al. Validating drug repurposing signals using electronic health records: A case study of metformin associated with reduced cancer mortality J. Am. Med. Inform. Assoc. 22 2015 179 191
9. Y.Y. Li, and S.J. Jones Drug repositioning for personalized medicine Genome Med. 4 2012 27
10. S.C. Fagan Drug repurposing for drug development in stroke Pharmacotherapy 30 2010 51S 54S
11. F. Imperi, and et al. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity Proc. Natl. Acad. Sci. U. S. A. 110 2013 7458 7463
12. M.A. Sukhai, and et al. New sources of drugs for hematologic malignancies Blood 117 2011 6747 6755
13. P.E. Cramer, and et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models Science 335 2012 1503 1506
14. D. Gero, and et al. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction Diabetes 62 2013 953 964
15. J. Ferlay, and et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 127 2010 2893 2917
16. S.C. Gupta, and et al. Cancer drug discovery by repurposing: teaching new tricks to old dogs Trends Pharmacol. Sci. 34 2013 508 517
17. M. Hay, and et al. Clinical development success rates for investigational drugs Nat. Biotechnol. 32 2014 40 51
18. R. Fisher, and et al. Cancer heterogeneity: implications for targeted therapeutics Br. J. Cancer 108 2013 479 485
19. T. Florio, and F. Barbieri The status of the art of human malignant glioma management: The promising role of targeting tumor-initiating cells Drug Discov. Today 17 2012 1103 1110
20. M.R. Junttila, and F.J. de Sauvage Influence of tumour micro-environment heterogeneity on therapeutic response Nature 501 2013 346 354
21. R. Wurth, and et al. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment Front. Cell. Neurosci. 8 2014 144
22. Y. Sun Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures Med. Res. Rev. 35 2015 408 436
23. F. Chen, and et al. New horizons in tumor microenvironment biology: challenges and opportunities BMC Med. 13 2015 45
24. M. Gatti, and et al. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity Toxicology 314 2013 209 220
25. D.W. McMillin, and et al. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities Nat. Rev. Drug Discov. 12 2013 217 228
26. R. Wurth, and et al. Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature J. Neuroimmunol. 234 2011 115 123
27. V. Kumar, and S. Chhibber Thalidomide: an old drug with new action J. Chemother. 23 2011 326 334
28. G. Bianchi, and et al. Promising therapies in multiple myeloma Blood 126 2015 300 310
29. G. Lu, and et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins Science 343 2014 305 309
30. M. Slingerland, and et al. Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials Invest. New Drugs 31 2013 1087 1094
31. + in apoptosis of CHO cells Cell Calcium 36 2004 421 430
32. H.A. Elbaz, and et al. Digitoxin and its analogs as novel cancer therapeutics Exp. Hematol. Oncol. 1 2012 4
33. L. Menger, and et al. Trial watch: cardiac glycosides and cancer therapy Oncoimmunology 2 2013 e23082
34. E.A. Platz, and et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment Cancer Discov. 1 2011 68 77
35. L. Menger, and et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death Sci. Transl. Med. 4 2012 143ra199
36. J. Triscott, and et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide Oncotarget 3 2012 1112 1123
37. A. Schafer, and et al. Aldehyde dehydrogenase 1A1: A new mediator of resistance to temozolomide in glioblastoma Neuro Oncol. 14 2012 1452 1464
38. P. Liu, and et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells Br. J. Cancer 107 2012 1488 1497
39. S.A. Choi, and et al. Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors Neuro Oncol. 17 2015 810 821
40. F.R. Kona, and et al. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies Curr. Cancer Drug Targets 11 2011 338 346
41. P. Liu, and et al. Liposome encapsulated Disulfiram inhibits NFkappaB pathway and targets breast cancer stem cells in vitro and in vivo Oncotarget 5 2014 7471 7485
42. J. Lin, and et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth Prostate 71 2011 333 343
43. S.M. Gough, and et al. NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function Cancer Discov. 4 2014 564 577
44. Y. Li, and et al. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas Cancer Lett. 2015 10.1016/j.canlet.2015.07.029
45. T. Chiba, and et al. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners PLOS ONE 9 2014 e84807
46. X. Duan, and et al. Multi-targeted inhibition of tumor growth and lung metastasis by redox-sensitive shell crosslinked micelles loading disulfiram Nanotechnology 25 2014 125102
47. J. Han, and et al. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts Toxicol. Appl. Pharmacol. 273 2013 477 483
48. J. Zha, and et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition J. Transl. Med. 12 2014 163
49. J. Triscott, and et al. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram Stem Cells 33 2015 1042 1046
50. B.T. Aftab, and et al. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer Cancer Res. 71 2011 6764 6772
51. R. Liu, and et al. Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking Autophagy 10 2014 1241 1255
52. J. Kim, and et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth Cancer Cell 17 2010 388 399
53. D.J. Kim, and et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma J. Clin. Oncol. 32 2014 745 751
54. J. Kim, and et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists Cancer Cell 23 2013 23 34
55. D.L. Suzman, and E.S. Antonarakis High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer Clin. Genitourin. Cancer 12 2014 e51 e53
56. H. Tsubamoto, and et al. Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer Anticancer Res. 34 2014 3839 3844
57. C.M. Rudin, and et al. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer J. Thorac. Oncol. 8 2013 619 623
58. H. Tsubamoto, and et al. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer Anticancer Res. 34 2014 2481 2487
59. H. Tsubamoto, and et al. Combination chemotherapy with itraconazole for treating metastatic pancreatic cancer in the second-line or additional setting Anticancer Res. 35 2015 4191 4196
60. B. Pasche, and et al. Prevention and treatment of cancer with aspirin: where do we stand? Semin. Oncol. 41 2014 397 401
61. C.M. Ulrich, and et al. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics Nat. Rev. Cancer 6 2006 130 140
62. J. Cuzick, and et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol. 10 2009 501 507
63. P.M. Rothwell, and et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 2012 1602 1612
64. P.M. Rothwell, and et al. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials Lancet 379 2012 1591 1601
65. S. Dilwali, and et al. Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas Transl. Res. 166 2015 1 11
66. M.A. Thorat, and J. Cuzick Role of aspirin in cancer prevention Curr. Oncol. Rep. 15 2013 533 540
67. A. Larocca, and et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Blood 119 2012 933 939 quiz 1093
68. I. Phillips, and et al. Aspirin as a treatment for cancer Clin. Oncol. 25 2013 333 335
69. S. Chen, and et al. Combined cancer therapy with non-conventional drugs: all roads lead to AMPK Mini Rev. Med. Chem. 14 2014 642 654
70. W. Yue, and et al. Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2 Oncotarget 6 2015 21208 21224
71. H. Yang, and et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression Cell Death Dis. 6 2015 e1786
72. G. Maity, and et al. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition Lab. Invest. 95 2015 702 717
73. Y. Zhang, and et al. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer Oncotarget 6 2015 9999 10015
74. C.M. Moon, and et al. Nonsteroidal anti-inflammatory drugs suppress cancer stem cells via inhibiting PTGS2 (cyclooxygenase 2) and NOTCH/HES1 and activating PPARG in colorectal cancer Int. J. Cancer 134 2014 519 529
75. E. Bastiaannet, and et al. Use of aspirin postdiagnosis improves survival for colon cancer patients Br. J. Cancer 106 2012 1564 1570
76. K. Ng, and et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer J. Natl. Cancer Inst. 107 2015 345
77. R.E. Kast, and et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care Oncotarget 4 2013 502 530
78. R.E. Kast, and et al. CUSP9∗treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide Oncotarget 5 2014 8052 8082
79. V.M. Dilman Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageine, and disease Lancet 1 1971 1211 1219
80. C. Bianchi, and et al. Treating the metabolic syndrome Expert Rev. Cardiovasc. Ther. 5 2007 491 506
81. A.J. Duleba Medical management of metabolic dysfunction in PCOS Steroids 77 2012 306 311
82. W.C. Knowler, and et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N. Engl. J. Med. 346 2002 393 403
83. Y. Shu, and et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action J. Clin. Invest. 117 2007 1422 1431
84. G. Zhou, and et al. Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 108 2001 1167 1174
85. M. Franciosi, and et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review PLoS ONE 8 2013 e71583
86. H. Noto, and et al. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis PLoS ONE 7 2012 e33411
87. M.J. Tsai, and et al. Metformin decreases lung cancer risk in diabetic patients in a dose-dependent manner Lung Cancer 86 2014 137 143
88. L. Wu, and et al. Pharmacologic therapy of diabetes and overall cancer risk and mortality: A meta-analysis of 265 studies Sci. Rep. 5 2015 10147
89. S. Orecchioni, and et al. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells Int. J. Cancer 136 2015 E534 E544
90. F. Barbieri, and et al. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors BMC Cancer 15 2015 228
91. A. Takahashi, and et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis Cancer Cell Int. 14 2014 53
92. H. Ashinuma, and et al. Antiproliferative action of metformin in human lung cancer cell lines Oncol. Rep. 28 2012 8 14
93. J. Yang, and et al. Metformin induces ER stress-dependent apoptosis through miR-708-5p/NNAT pathway in prostate cancer Oncogenesis 4 2015 e158
94. A. Sikka, and et al. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation Cell Cycle 11 2012 1374 1382
95. J. Sesen, and et al. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response PLOS ONE 10 2015 e0123721
96. A. Kumar, and et al. Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma Oncotarget 5 2014 11709 11722
97. D. Costa, and et al. Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA Cancer Cell Int. 14 2014 59
98. F.M. Zi, and et al. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models Cancer Lett. 356 2015 443 453
99. S. Jagannathan, and et al. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib Leukemia. 2015 10.1038/leu.2015.157
100. G.M. Leclerc, and et al. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts PLoS ONE 8 2013 e74420
101. R.J. Dowling, and et al. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: A prospective window of opportunity neoadjuvant study Breast Cancer Res. 17 2015 32
102. V. Hanusova, and et al. Potential anti-cancer drugs commonly used for other indications Curr. Cancer Drug Targets 15 2015 35 52
103. S. Del Barco, and et al. Metformin: multi-faceted protection against cancer Oncotarget 2 2011 896 917
104. I. Ben Sahra, and et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1 Cancer Res. 71 2011 4366 4372
105. X. Liu, and et al. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK Proc. Natl. Acad. Sci. U. S. A. 111 2014 E435 E444
106. C. Marini, and et al. Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer Cell Cycle 12 2013 3490 3499
107. D.A. Iglesias, and et al. Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy Mol. Cancer Ther. 12 2013 2847 2856
108. S. Eikawa, and et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin Proc. Natl. Acad. Sci. U. S. A. 112 2015 1809 1814
109. B. Bao, and et al. Metformin may function as anti-cancer agent via targeting cancer stem cells: The potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers Ann. Transl. Med. 2 2014 59
110. R. Wurth, and et al. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells Biomed. Res. Int. 2014 2014 126586
111. H.A. Hirsch, and et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission Cancer Res. 69 2009 7507 7511
112. A. Vazquez-Martin, and et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells Breast Cancer Res. Treat. 126 2011 355 364
113. S. Cufi, and et al. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts Oncotarget 3 2012 395 398
114. E. Lonardo, and et al. Studying pancreatic cancer stem cell characteristics for developing new treatment strategies J. Vis. Exp. 100 2015 e52801
115. R. Wurth, and et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt Cell Cycle 12 2013 145 156
116. D. Iliopoulos, and et al. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types Cancer Res. 71 2011 3196 3201
117. N.Y. Kim, and et al. Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells Int. J. Oncol. 47 2015 353 360
118. G. Yu, and et al. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice Oncotarget 6 2015 12748 12762
119. P.P. Liu, and et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway Cell Death Differ. 21 2014 124 135
120. J.A. Menendez, and et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells Cell Cycle 12 2013 1166 1179
121. S. Yuan, and et al. Effective elimination of cancer stem cells by a novel drug combination strategy Stem Cells 31 2013 23 34
122. J.A. Menendez, and et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells Cell Cycle 11 2012 2782 2792
123. H.A. Hirsch, and et al. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth Proc. Natl. Acad. Sci. U. S. A. 110 2013 972 977
124. R.U. Takahashi, and et al. Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ENPP1 Nat. Commun. 6 2015 7318
125. M. Gritti, and et al. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current Oncotarget 5 2014 11252 11268
126. M. Setti, and et al. Functional role of CLIC1 ion channel in glioblastoma-derived stem/progenitor cells J. Natl. Cancer Inst. 105 2013 1644 1655
127. M. Peretti, and et al. Chloride channels in cancer: focus on chloride intracellular channel 1 and 4 (CLIC! and CLIC4) proteins in tumor development and as novel therapeutic targets Biochim. Biophys. Acta 1848 10 2015 2523 2531